The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ewing sarcoma Family of Tumors in Older Patients (EFyTOP): Management and outcome of Ewing sarcoma family of tumors (EFTs) in patients older than 50 years.
 
Pauline Rochefort
No Relationships to Disclose
 
Antoine Italiano
Honoraria - GlaxoSmithKline; Merck; PharmaMar
Consulting or Advisory Role - Janssen (Inst)
Research Funding - Pfizer (Inst); PharmaMar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
 
Valerie Laurence
No Relationships to Disclose
 
Nicolas Penel
Research Funding - PharmaMar (Inst)
 
Audrey Lardy-Cleaud
No Relationships to Disclose
 
Olivier Mir
Honoraria - Amgen; AstraZeneca; Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Christine Chevreau
No Relationships to Disclose
 
Francois Bertucci
No Relationships to Disclose
 
Emmanuelle Bompas
No Relationships to Disclose
 
Loic Chaigneau
No Relationships to Disclose
 
Dominique Levy
No Relationships to Disclose
 
Thomas Ryckewaert
No Relationships to Disclose
 
Sarah Naomie Dumont
No Relationships to Disclose
 
Pierre Meeus
No Relationships to Disclose
 
Dominique Ranchere
No Relationships to Disclose
 
Jean-Yves Blay
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pharmamar; Roche
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Merck; Novartis; PharmaMar; Roche
Research Funding - GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst)
 
Philippe Alexandre Cassier
Honoraria - Blueprint Medicines; Novartis; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Celgene (Inst); Lilly (Inst); Novartis (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Amgen; Novartis; Roche